Erbitux Misses Primary Endpoint As First-Line Treatment In Phase III NSCLC Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb/ImClone’s future for Erbitux in first-line NSCLC hinges on FLEX study findings, scheduled for release in first half of 2008.